InvestorsHub Logo
Followers 20
Posts 3254
Boards Moderated 1
Alias Born 06/05/2020

Re: Emergcy post# 185251

Tuesday, 09/21/2021 7:34:00 PM

Tuesday, September 21, 2021 7:34:00 PM

Post# of 233220
I agree--but some companies do not. This biotech gave their CEO the boot and he had gotten them 2 FDA approvals. Started talking about secondary ETC and they fired him

https://endpts.com/aerie-fires-ceo-after-lead-program-flops/
_________________________________________________________________________
Things took a sour turn more recently, however, after Aerie revealed a mid-stage study did not hit statistical significance last week.
The dry eye disease trial missed all of its primary endpoints, but Anido asserted the endpoints were “not required” because the trial is a Phase IIb study, a statement that rankled outside observers and investors.

yowser
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News